{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:13:11Z","timestamp":1790507591269,"version":"4.1.0"},"reference-count":246,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T00:00:00Z","timestamp":1580860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>The proteasome is the central component of the main cellular protein degradation pathway. During the past four decades, the critical function of the proteasome in numerous physiological processes has been revealed, and proteasome activity has been linked to various human diseases. The proteasome prevents the accumulation of misfolded proteins, controls the cell cycle, and regulates the immune response, to name a few important roles for this macromolecular \u201cmachine.\u201d As a therapeutic target, proteasome inhibitors have been approved for the treatment of multiple myeloma and mantle cell lymphoma. However, inability to sufficiently inhibit proteasome activity at tolerated doses has hampered efforts to expand the scope of proteasome inhibitor-based therapies. With emerging new modalities in myeloma, it might seem challenging to develop additional proteasome-based therapies. However, the constant development of new applications for proteasome inhibitors and deeper insights into the intricacies of protein homeostasis suggest that proteasome inhibitors might have novel therapeutic applications. Herein, we summarize the latest advances in proteasome inhibitor development and discuss the future of proteasome inhibitors and other proteasome-based therapies in combating human diseases.<\/jats:p>","DOI":"10.3390\/molecules25030671","type":"journal-article","created":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T11:50:28Z","timestamp":1581076228000},"page":"671","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Proteasome Inhibitors: Harnessing Proteostasis to Combat Disease"],"prefix":"10.3390","volume":"25","author":[{"given":"David J.","family":"Sherman","sequence":"first","affiliation":[{"name":"Amgen Research, Amgen Inc., Thousand Oaks, CA 91320, USA"},{"name":"Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[{"name":"Biochemical and Cellular Pharmacology, Genentech Inc., South San Francisco, CA 94080, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,2,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nature19947","article-title":"Proteome complexity and the forces that drive proteome imbalance","volume":"537","author":"Harper","year":"2016","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Hershey, J.W., Sonenberg, N., and Mathews, M.B. (2012). Principles of translational control: An overview. Cold Spring Harb. Perspect. Biol.","DOI":"10.1101\/cshperspect.a011528"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ceb.2011.01.004","article-title":"Protein homeostasis networks in physiology and disease","volume":"23","author":"Hetz","year":"2011","journal-title":"Curr. Opin. Cell Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1146\/annurev-biochem-060614-033955","article-title":"The biology of proteostasis in aging and disease","volume":"84","author":"Labbadia","year":"2015","journal-title":"Annu. Rev. Biochem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev.biochem.67.1.425","article-title":"The ubiquitin system","volume":"67","author":"Hershko","year":"1998","journal-title":"Annu. Rev. Biochem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1152\/physrev.00027.2001","article-title":"The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction","volume":"82","author":"Glickman","year":"2002","journal-title":"Physiol. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1074-5521(01)00056-4","article-title":"Proteasome inhibitors: From research tools to drug candidates","volume":"8","author":"Kisselev","year":"2001","journal-title":"Chem. Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1146\/annurev.biochem.78.081507.101607","article-title":"Recognition and processing of ubiquitin-protein conjugates by the proteasome","volume":"78","author":"Finley","year":"2009","journal-title":"Annu. Rev. Biochem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1177\/1947601910383011","article-title":"The Unfolded Protein Response, Degradation from Endoplasmic Reticulum and Cancer","volume":"1","author":"Tsai","year":"2010","journal-title":"Genes Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1126\/science.1209038","article-title":"The unfolded protein response: From stress pathway to homeostatic regulation","volume":"334","author":"Walter","year":"2011","journal-title":"Science"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1172\/JCI11991","article-title":"Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB","volume":"107","author":"Baldwin","year":"2001","journal-title":"J. Clin. Investig."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1089\/ars.2006.8.478","article-title":"NF-kappaB: A stress-regulated switch for cell survival","volume":"8","author":"Piva","year":"2006","journal-title":"Antioxid. Redox Signal."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.trsl.2018.05.002","article-title":"Aim for the core: Suitability of the ubiquitin-independent 20S proteasome as a drug target in neurodegeneration","volume":"198","author":"Gestwicki","year":"2018","journal-title":"Transl. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/nrn2499","article-title":"Ubiquitin, the proteasome and protein degradation in neuronal function and dysfunction","volume":"9","author":"Tai","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nsmb.3389","article-title":"A mammalian nervous-system-specific plasma membrane proteasome complex that modulates neuronal function","volume":"24","author":"Ramachandran","year":"2017","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1146\/annurev-biochem-062917-011931","article-title":"Structure and Function of the 26S Proteasome","volume":"87","author":"Bard","year":"2018","journal-title":"Annu. Rev. Biochem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1124\/pr.117.015370","article-title":"A Practical Review of Proteasome Pharmacology","volume":"71","author":"Thibaudeau","year":"2019","journal-title":"Pharm. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.chembiol.2012.01.003","article-title":"Proteasome inhibitors: An expanding army attacking a unique target","volume":"19","author":"Kisselev","year":"2012","journal-title":"Chem. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bbamcr.2013.08.012","article-title":"Regulation of proteasome activity in health and disease","volume":"1843","author":"Schmidt","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1021\/acscentsci.7b00252","article-title":"The Proteasome in Modern Drug Discovery: Second Life of a Highly Valuable Drug Target","volume":"3","author":"Cromm","year":"2017","journal-title":"ACS Cent. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Lobanova, E.S., Finkelstein, S., Li, J., Travis, A.M., Hao, Y., Klingeborn, M., Skiba, N.P., Deshaies, R.J., and Arshavsky, V.Y. (2018). Increased proteasomal activity supports photoreceptor survival in inherited retinal degeneration. Nat. Commun.","DOI":"10.1038\/s41467-018-04117-8"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1073\/pnas.74.1.54","article-title":"A soluble ATP-dependent proteolytic system responsible for the degradation of abnormal proteins in reticulocytes","volume":"74","author":"Etlinger","year":"1977","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"16209","DOI":"10.1016\/S0021-9258(18)37580-X","article-title":"Proteasomes (multi-protease complexes) as 20 S ring-shaped particles in a variety of eukaryotic cells","volume":"263","author":"Tanaka","year":"1988","journal-title":"J. Biol. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/331192a0","article-title":"Identity of the 19S \u201cprosome\u201d particle with the large multifunctional protease complex of mammalian cells (the proteasome)","volume":"331","author":"Arrigo","year":"1988","journal-title":"Nature"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1146\/annurev-biochem-060408-172623","article-title":"AAA+ proteases: ATP-fueled machines of protein destruction","volume":"80","author":"Sauer","year":"2011","journal-title":"Annu. Rev. Biochem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.cell.2017.04.023","article-title":"The Logic of the 26S Proteasome","volume":"169","author":"Collins","year":"2017","journal-title":"Cell"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/(SICI)1097-0282(1997)43:4<269::AID-BIP2>3.0.CO;2-T","article-title":"Proteasome inhibitors and antigen presentation","volume":"43","author":"Bogyo","year":"1997","journal-title":"Biopolymers"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/80992","article-title":"A gated channel into the proteasome core particle","volume":"7","author":"Groll","year":"2000","journal-title":"Nat. Struct. Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/35040607","article-title":"Structural basis for the activation of 20S proteasomes by 11S regulators","volume":"408","author":"Whitby","year":"2000","journal-title":"Nature"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.tibs.2015.10.009","article-title":"Gates, Channels, and Switches: Elements of the Proteasome Machine","volume":"41","author":"Finley","year":"2016","journal-title":"Trends Biochem. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev-biophys-083012-130417","article-title":"Structural biology of the proteasome","volume":"42","author":"Hill","year":"2013","journal-title":"Annu. Rev. Biophys."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/emboj\/19.1.94","article-title":"Recognition of the polyubiquitin proteolytic signal","volume":"19","author":"Thrower","year":"2000","journal-title":"EMBO J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0092-8674(00)80843-0","article-title":"A proteasome howdunit: The case of the missing signal","volume":"101","author":"Verma","year":"2000","journal-title":"Cell"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1128\/MCB.18.6.3149","article-title":"The regulatory particle of the Saccharomyces cerevisiae proteasome","volume":"18","author":"Glickman","year":"1998","journal-title":"Mol. Cell Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1126\/science.1075898","article-title":"Role of Rpn11 metalloprotease in deubiquitination and degradation by the 26S proteasome","volume":"298","author":"Verma","year":"2002","journal-title":"Science"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.molcel.2017.07.023","article-title":"An AAA Motor-Driven Mechanical Switch in Rpn11 Controls Deubiquitination at the 26S Proteasome","volume":"67","author":"Worden","year":"2017","journal-title":"Mol. Cell"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0305-7372(03)00083-5","article-title":"Therapeutic anti-cancer targets upstream of the proteasome","volume":"29","author":"Nalepa","year":"2003","journal-title":"Cancer Treat. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.chembiol.2018.07.012","article-title":"Epidithiodiketopiperazines Inhibit Protein Degradation by Targeting Proteasome Deubiquitinase Rpn11","volume":"25","author":"Li","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nchembio.2370","article-title":"Thiolutin is a zinc chelator that inhibits the Rpn11 and other JAMM metalloproteases","volume":"13","author":"Lauinger","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nchembio.2326","article-title":"Capzimin is a potent and specific inhibitor of proteasome isopeptidase Rpn11","volume":"13","author":"Li","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1006\/bbrc.2000.3676","article-title":"Tissue distribution of constitutive proteasomes, immunoproteasomes, and PA28 in rats","volume":"277","author":"Noda","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"10515","DOI":"10.1016\/S0021-9258(19)50047-3","article-title":"Identification, purification, and characterization of a protein activator (PA28) of the 20 S proteasome (macropain)","volume":"267","author":"Ma","year":"1992","journal-title":"J. Biol. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"22369","DOI":"10.1016\/S0021-9258(18)41681-X","article-title":"Purification of an 11 S regulator of the multicatalytic protease","volume":"267","author":"Dubiel","year":"1992","journal-title":"J. Biol. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/37670","article-title":"Structure of the proteasome activator REGalpha (PA28alpha)","volume":"390","author":"Knowlton","year":"1997","journal-title":"Nature"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"25483","DOI":"10.1074\/jbc.272.41.25483","article-title":"Characterization of recombinant REGalpha, REGbeta, and REGgamma proteasome activators","volume":"272","author":"Realini","year":"1997","journal-title":"J. Biol. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0161-5890(02)00099-8","article-title":"The role of the proteasome activator PA28 in MHC class I antigen processing","volume":"39","author":"Sijts","year":"2002","journal-title":"Mol. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/381166a0","article-title":"A role for the proteasome regulator PA28alpha in antigen presentation","volume":"381","author":"Groettrup","year":"1996","journal-title":"Nature"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.molcel.2007.05.028","article-title":"Ubiquitin- and ATP-independent proteolytic turnover of p21 by the REGgamma-proteasome pathway","volume":"26","author":"Li","year":"2007","journal-title":"Mol. Cell"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.molcel.2007.05.022","article-title":"Ubiquitin-independent degradation of cell-cycle inhibitors by the REGgamma proteasome","volume":"26","author":"Chen","year":"2007","journal-title":"Mol. Cell"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.molcel.2010.02.002","article-title":"Structure of a Blm10 complex reveals common mechanisms for proteasome binding and gate opening","volume":"37","author":"Whitby","year":"2010","journal-title":"Mol. Cell"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/sj.embor.embor938","article-title":"Blm3 is part of nascent proteasomes and is involved in a late stage of nuclear proteasome assembly","volume":"4","author":"Fehlker","year":"2003","journal-title":"EMBO Rep."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/yea.1146","article-title":"Expression of the expanded YFL007w ORF and assignment of the gene name BLM10","volume":"21","author":"Doherty","year":"2004","journal-title":"Yeast"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1093\/emboj\/cdf333","article-title":"PA200, a nuclear proteasome activator involved in DNA repair","volume":"21","author":"Ustrell","year":"2002","journal-title":"EMBO J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"42830","DOI":"10.1074\/jbc.M111.300178","article-title":"Blm10 protein promotes proteasomal substrate turnover by an active gating mechanism","volume":"286","author":"Dange","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1021\/pr500193k","article-title":"Label-free quantitative proteomics reveals the dynamics of proteasome complexes composition and stoichiometry in a wide range of human cell lines","volume":"13","author":"Fabre","year":"2014","journal-title":"J. Proteome Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"13147","DOI":"10.1074\/jbc.M116.717652","article-title":"Inhibition of Proteasome Activity Induces Formation of Alternative Proteasome Complexes","volume":"291","author":"Welk","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.molcel.2019.07.014","article-title":"Characterization of Fully Recombinant Human 20S and 20S-PA200 Proteasome Complexes","volume":"76","year":"2019","journal-title":"Mol. Cell"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1006\/jmbi.2001.5063","article-title":"Reconstitution of hybrid proteasomes from purified PA700-20 S complexes and PA28alphabeta activator: Ultrastructure and peptidase activities","volume":"313","author":"Kopp","year":"2001","journal-title":"J. Mol. Biol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.abb.2015.12.012","article-title":"Mammalian proteasome subtypes: Their diversity in structure and function","volume":"591","author":"Dahlmann","year":"2016","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1093\/emboj\/21.11.2636","article-title":"Properties of the hybrid form of the 26S proteasome containing both 19S and PA28 complexes","volume":"21","author":"Cascio","year":"2002","journal-title":"EMBO J."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.jmb.2008.12.081","article-title":"Proteasomes can degrade a significant proportion of cellular proteins independent of ubiquitination","volume":"386","author":"Baugh","year":"2009","journal-title":"J. Mol. Biol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.bbamcr.2013.05.008","article-title":"Ubiquitin-independent proteasomal degradation","volume":"1843","author":"Erales","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1093\/emboj\/cdg158","article-title":"Determinants of proteasome recognition of ornithine decarboxylase, a ubiquitin-independent substrate","volume":"22","author":"Zhang","year":"2003","journal-title":"EMBO J."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/360597a0","article-title":"Ornithine decarboxylase is degraded by the 26S proteasome without ubiquitination","volume":"360","author":"Murakami","year":"1992","journal-title":"Nature"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/B978-0-12-397863-9.00003-1","article-title":"Immunoproteasomes: Structure, function, and antigen presentation","volume":"109","author":"Ferrington","year":"2012","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Kimura, H., Caturegli, P., Takahashi, M., and Suzuki, K. (2015). New Insights into the Function of the Immunoproteasome in Immune and Nonimmune Cells. J. Immunol. Res.","DOI":"10.1155\/2015\/541984"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2776(02)80012-8","article-title":"Protein degradation and the generation of MHC class I-presented peptides","volume":"80","author":"Rock","year":"2002","journal-title":"Adv. Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/jlb.56.5.571","article-title":"Role of proteasomes modified by interferon-gamma in antigen processing","volume":"56","author":"Tanaka","year":"1994","journal-title":"J. Leukoc. Biol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/1074-7613(94)90043-4","article-title":"Altered peptidase and viral-specific T cell response in LMP2 mutant mice","volume":"1","author":"Eichelberger","year":"1994","journal-title":"Immunity"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/365264a0","article-title":"Gamma-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes","volume":"365","author":"Gaczynska","year":"1993","journal-title":"Nature"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1111\/ajt.14435","article-title":"The immunoproteasome: An old player with a novel and emerging role in alloimmunity","volume":"17","author":"Eskandari","year":"2017","journal-title":"Am. J. Transpl."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/s41590-018-0186-z","article-title":"The immunoproteasome and thymoproteasome: Functions, evolution and human disease","volume":"19","author":"Murata","year":"2018","journal-title":"Nat. Immunol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"9241","DOI":"10.1073\/pnas.0501711102","article-title":"IFN-gamma-induced immune adaptation of the proteasome system is an accelerated and transient response","volume":"102","author":"Heink","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1084\/jem.187.1.97","article-title":"Immunoproteasome assembly: Cooperative incorporation of interferon gamma (IFN-gamma)-inducible subunits","volume":"187","author":"Griffin","year":"1998","journal-title":"J. Exp. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.bbamcr.2004.09.025","article-title":"Inhibitors of the eukaryotic 20S proteasome core particle: A structural approach","volume":"1695","author":"Groll","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2174\/156800911794519725","article-title":"Second generation proteasome inhibitors: Carfilzomib and immunoproteasome-specific inhibitors (IPSIs)","volume":"11","author":"Kuhn","year":"2011","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_77","first-page":"74","article-title":"The immunoproteasome: A novel drug target for autoimmune diseases","volume":"33","author":"Basler","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Santos, R.L.A., Bai, L., Singh, P.K., Murakami, N., Fan, H., Zhan, W., Zhu, Y., Jiang, X., Zhang, K., and Assker, J.P. (2017). Structure of human immunoproteasome with a reversible and noncompetitive inhibitor that selectively inhibits activated lymphocytes. Nat. Commun.","DOI":"10.1038\/s41467-017-01760-5"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.cell.2011.12.030","article-title":"Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity","volume":"148","author":"Huber","year":"2012","journal-title":"Cell"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1126\/science.1141915","article-title":"Regulation of CD8+ T cell development by thymus-specific proteasomes","volume":"316","author":"Murata","year":"2007","journal-title":"Science"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Sasaki, K., Takada, K., Ohte, Y., Kondo, H., Sorimachi, H., Tanaka, K., Takahama, Y., and Murata, S. (2015). Thymoproteasomes produce unique peptide motifs for positive selection of CD8(+) T cells. Nat. Commun.","DOI":"10.1038\/ncomms8484"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.tibs.2013.10.004","article-title":"The unique functions of tissue-specific proteasomes","volume":"39","author":"Kniepert","year":"2014","journal-title":"Trends Biochem. Sci."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1128\/MCB.26.8.2999-3007.2006","article-title":"Proteasome activator PA200 is required for normal spermatogenesis","volume":"26","author":"Khor","year":"2006","journal-title":"Mol. Cell Biol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.cell.2013.04.032","article-title":"Acetylation-mediated proteasomal degradation of core histones during DNA repair and spermatogenesis","volume":"153","author":"Qian","year":"2013","journal-title":"Cell"},{"key":"ref_85","unstructured":"(2017). BioRender.com, version 2017; M5V 2B7, Created Graphical Illustrations, BioRender 2017\u20132020, BioRender Customer Service."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0962-8924(98)01346-4","article-title":"Proteasome inhibitors: Valuable new tools for cell biologists","volume":"8","author":"Lee","year":"1998","journal-title":"Trends Cell Biol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1083\/jcb.110.5.1501","article-title":"Membrane biogenesis during B cell differentiation: Most endoplasmic reticulum proteins are expressed coordinately","volume":"110","author":"Wiest","year":"1990","journal-title":"J. Cell Biol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1158\/0008-5472.CAN-06-2258","article-title":"Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition","volume":"67","author":"Meister","year":"2007","journal-title":"Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Deshaies, R.J. (2014). Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy. BMC Biol.","DOI":"10.1186\/s12915-014-0094-0"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1126\/science.1209235","article-title":"Road to ruin: Targeting proteins for degradation in the endoplasmic reticulum","volume":"334","author":"Smith","year":"2011","journal-title":"Science"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"5745","DOI":"10.1002\/anie.201600190","article-title":"Nonpeptidic Selective Inhibitors of the Chymotrypsin-Like (\u03b25\u2009i) Subunit of the Immunoproteasome","volume":"55","author":"Gobec","year":"2016","journal-title":"Angew. Chem. Int. Ed Engl."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/cbic.201700021","article-title":"Structural Elucidation of a Nonpeptidic Inhibitor Specific for the Human Immunoproteasome","volume":"18","author":"Cui","year":"2017","journal-title":"Chembiochem Eur. J. Chem. Biol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1021\/acs.jmedchem.7b00318","article-title":"The Current State of Peptide Drug Discovery: Back to the Future?","volume":"61","author":"Henninot","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1016\/j.bmc.2017.06.052","article-title":"Therapeutic peptides: Historical perspectives, current development trends, and future directions","volume":"26","author":"Lau","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1158\/1078-0432.CCR-06-0170","article-title":"United States Food and Drug Administration approval summary: Bortezomib for the treatment of progressive multiple myeloma after one prior therapy","volume":"12","author":"Kane","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: Results of the randomized phase III HOVON-65\/GMMG-HD4 trial","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-06-4086","article-title":"Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome","volume":"67","author":"Demo","year":"2007","journal-title":"Cancer Res."},{"key":"ref_99","first-page":"508","article-title":"Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy","volume":"8","author":"Kane","year":"2003","journal-title":"Oncology"},{"key":"ref_100","first-page":"2505","article-title":"A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies","volume":"8","author":"Aghajanian","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ccr.2007.07.004","article-title":"Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma","volume":"12","author":"Annunziata","year":"2007","journal-title":"Cancer Cell"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ccr.2007.07.003","article-title":"Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma","volume":"12","author":"Keats","year":"2007","journal-title":"Cancer Cell"},{"key":"ref_103","first-page":"3071","article-title":"The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells","volume":"61","author":"Hideshima","year":"2001","journal-title":"Cancer Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"16639","DOI":"10.1074\/jbc.M200360200","article-title":"NF-kappa B as a therapeutic target in multiple myeloma","volume":"277","author":"Hideshima","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1158\/0008-5472.CAN-09-2766","article-title":"Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer","volume":"70","author":"Kupperman","year":"2010","journal-title":"Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1021\/jm801329v","article-title":"Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047)","volume":"52","author":"Zhou","year":"2009","journal-title":"J. Med. Chem."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2007-08-104950","article-title":"Molecular basis of bortezomib resistance: Proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein","volume":"112","author":"Oerlemans","year":"2008","journal-title":"Blood"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1124\/jpet.108.138131","article-title":"Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma\/leukemia line","volume":"326","author":"Yang","year":"2008","journal-title":"J. Pharm. Exp. Ther."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1038\/leu.2009.8","article-title":"Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells","volume":"23","author":"Kraus","year":"2009","journal-title":"Leukemia"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1182\/blood-2011-10-386789","article-title":"Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma","volume":"120","author":"Kuhn","year":"2012","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"14374","DOI":"10.1073\/pnas.202445099","article-title":"Molecular sequelae of proteasome inhibition in human multiple myeloma cells","volume":"99","author":"Mitsiades","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_112","first-page":"18","article-title":"Molecular basis of resistance to proteasome inhibitors in hematological malignancies","volume":"18","author":"Niewerth","year":"2015","journal-title":"Drug Resist. Updat. Rev. Comment Antimicrob. Anticancer Chemother."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.2217\/fon.14.30","article-title":"Efficacy of therapy with bortezomib in solid tumors: A review based on 32 clinical trials","volume":"10","author":"Huang","year":"2014","journal-title":"Future Oncol. Lond. Engl."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1039\/c3np20126k","article-title":"From epoxomicin to carfilzomib: Chemistry, biology, and medical outcomes","volume":"30","author":"Kim","year":"2013","journal-title":"Nat. Prod. Rep."},{"key":"ref_116","first-page":"418","article-title":"Crystal structure of the human 20S proteasome in complex with carfilzomib","volume":"23","author":"Harshbarger","year":"2015","journal-title":"Struct. Lond. Engl. 1993"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): A randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): An interim overall survival analysis of an open-label, randomised, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41375-019-0517-6","article-title":"Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma","volume":"33","author":"Landgren","year":"2019","journal-title":"Leukemia"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Waxman, A.J., Clasen, S., Hwang, W.-T., Garfall, A., Vogl, D.T., Carver, J., O\u2019Quinn, R., Cohen, A.D., Stadtmauer, E.A., and Ky, B. (2018). Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis. JAMA Oncol.","DOI":"10.1001\/jamaoncol.2017.4519"},{"key":"ref_121","first-page":"585","article-title":"Cardiovascular events during carfilzomib therapy for relapsed myeloma: Practical management aspects from two case studies","volume":"22","author":"Jakubowiak","year":"2017","journal-title":"Hematol. Amst. Neth."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1080\/10428194.2017.1403020","article-title":"Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity","volume":"59","author":"Lendvai","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00280-013-2267-x","article-title":"A phase I\/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors","volume":"72","author":"Papadopoulos","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s40265-016-0548-5","article-title":"Ixazomib: First Global Approval","volume":"76","author":"Shirley","year":"2016","journal-title":"Drugs"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.drudis.2010.01.008","article-title":"Building on bortezomib: Second-generation proteasome inhibitors as anti-cancer therapy","volume":"15","author":"Dick","year":"2010","journal-title":"Drug Discov. Today"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/bjh.14987","article-title":"A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): Final study results","volume":"180","author":"Spencer","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1158\/1535-7163.MCT-06-0066","article-title":"The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia","volume":"5","author":"Ruiz","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1021\/ja058320b","article-title":"Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding","volume":"128","author":"Groll","year":"2006","journal-title":"J. Am. Chem. Soc."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2174\/156800911794519716","article-title":"Marizomib, a proteasome inhibitor for all seasons: Preclinical profile and a framework for clinical trials","volume":"11","author":"Potts","year":"2011","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1021\/jm048995+","article-title":"Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor","volume":"48","author":"Macherla","year":"2005","journal-title":"J. Med. Chem."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-15-2616","article-title":"Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results","volume":"22","author":"Harrison","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/neuonc\/nov299","article-title":"Marizomib activity as a single agent in malignant gliomas: Ability to cross the blood-brain barrier","volume":"18","author":"Di","year":"2016","journal-title":"Neuro-Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Manton, C.A., Johnson, B., Singh, M., Bailey, C.P., Bouchier-Hayes, L., and Chandra, J. (2016). Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo. Sci. Rep.","DOI":"10.1038\/srep18953"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Weller, M., Le Rhun, E., Preusser, M., Tonn, J.-C., and Roth, P. (2019). How we treat glioblastoma. Esmo Open.","DOI":"10.1136\/esmoopen-2019-000520"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1182\/blood-2010-04-276626","article-title":"A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma","volume":"116","author":"Chauhan","year":"2010","journal-title":"Blood"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1158\/1078-0432.CCR-18-3728","article-title":"A Phase Ib\/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenstr\u00f6m Macroglobulinemia","volume":"25","author":"Ghobrial","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Hari, P., Matous, J.V., Voorhees, P.M., Shain, K.H., Obreja, M., Frye, J., Fujii, H., Jakubowiak, A.J., Rossi, D., and Sonneveld, P. (2019). Oprozomib in patients with newly diagnosed multiple myeloma. Blood Cancer J.","DOI":"10.1038\/s41408-019-0232-6"},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Hari, P., Paba-Prada, C.E., Voorhees, P.M., Frye, J., Chang, Y.-L., Moreau, P., Zonder, J., Boccia, R., and Shain, K.H. (2019). Efficacy and safety results from a phase 1b\/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and\/or refractory multiple myeloma. Leuk. Res.","DOI":"10.1016\/j.leukres.2019.106172"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.clml.2019.05.017","article-title":"Oprozomib, pomalidomide, and Dexamethasone in Patients with Relapsed and\/or Refractory Multiple Myeloma","volume":"19","author":"Shah","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s10637-016-0327-x","article-title":"A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors","volume":"34","author":"Infante","year":"2016","journal-title":"Investig. New Drugs"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"11127","DOI":"10.1021\/acs.jmedchem.8b01201","article-title":"Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2 S,3 R)- N-((S)-3-(Cyclopent-1-en-1-yl)-1-((R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propenamide)","volume":"61","author":"Johnson","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/nm.1978","article-title":"A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis","volume":"15","author":"Muchamuel","year":"2009","journal-title":"Nat. Med."},{"key":"ref_143","first-page":"1756","article-title":"PR-957, a selective inhibitor of immunoproteasome subunit low-MW polypeptide 7, attenuates experimental autoimmune neuritis by suppressing Th17-cell differentiation and regulating cytokine production","volume":"31","author":"Liu","year":"2017","journal-title":"FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1556\/1886.2017.00025","article-title":"Low Neurotoxicity of ONX-0914 Supports the Idea of Specific Immunoproteasome Inhibition as a Side-Effect-Limiting, Therapeutic Strategy","volume":"7","author":"Landgraf","year":"2017","journal-title":"Eur. J. Microbiol. Immunol."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Sanderson, M., Busch, M., Esdar, C., Friese-Hamim, M., Krier, M., Ma, J., Musil, D., Rohdich, F., Sloot, W., and Walter, G. (2019). Abstract DDT02-01: First-time disclosure of M3258: A selective inhibitor of the immunoproteasome subunit LMP7 with potential for improved therapeutic utility in multiple myeloma compared to pan-proteasome inhibitors. Proceedings of the Molecular and Cellular Biology\/Genetics, American Association for Cancer Research.","DOI":"10.1158\/1538-7445.SABCS18-DDT02-01"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/nature01071","article-title":"A cryptic protease couples deubiquitination and degradation by the proteasome","volume":"419","author":"Yao","year":"2002","journal-title":"Nature"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/anie.201608672","article-title":"Azaindoles as Zinc-Binding Small-Molecule Inhibitors of the JAMM Protease CSN5","volume":"56","author":"Altmann","year":"2017","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"11460","DOI":"10.1021\/bi035033g","article-title":"Structure of the Jab1\/MPN domain and its implications for proteasome function","volume":"42","author":"Tran","year":"2003","journal-title":"Biochemistry"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1158\/1535-7163.MCT-06-0542","article-title":"The JAMM motif of human deubiquitinase Poh1 is essential for cell viability","volume":"6","author":"Gallery","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1021\/acs.jmedchem.6b01379","article-title":"Discovery of an Inhibitor of the Proteasome Subunit Rpn11","volume":"60","author":"Perez","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1126\/science.1100946","article-title":"Ubistatins inhibit proteasome-dependent degradation by binding the ubiquitin chain","volume":"306","author":"Verma","year":"2004","journal-title":"Science"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/j.str.2017.10.007","article-title":"Structural Basis for the Inhibitory Effects of Ubistatins in the Ubiquitin-Proteasome Pathway","volume":"25","author":"Nakasone","year":"2017","journal-title":"Structure"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"8773","DOI":"10.1074\/jbc.M115.694588","article-title":"The Proteasome Ubiquitin Receptor hRpn13 and Its Interacting Deubiquitinating Enzyme Uch37 Are Required for Proper Cell Cycle Progression","volume":"291","author":"Randles","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_154","first-page":"531","article-title":"Knockdown of the novel proteasome subunit Adrm1 located on the 20q13 amplicon inhibits colorectal cancer cell migration, survival and tumorigenicity","volume":"21","author":"Chen","year":"2009","journal-title":"Oncol. Rep."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/gcc.20592","article-title":"Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target","volume":"47","author":"Fejzo","year":"2008","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s10585-014-9663-4","article-title":"ADRM1 gene amplification is a candidate driver for metastatic gastric cancers","volume":"31","author":"Jang","year":"2014","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1038\/leu.2016.97","article-title":"Targeting proteasome ubiquitin receptor Rpn13 in multiple myeloma","volume":"30","author":"Song","year":"2016","journal-title":"Leukemia"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.ccr.2013.11.001","article-title":"A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13\/ADRM1 as a therapy for cancer","volume":"24","author":"Anchoori","year":"2013","journal-title":"Cancer Cell"},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Lu, X., Nowicka, U., Sridharan, V., Liu, F., Randles, L., Hymel, D., Dyba, M., Tarasov, S.G., Tarasova, N.I., and Zhao, X.Z. (2017). Structure of the Rpn13-Rpn2 complex provides insights for Rpn13 and Uch37 as anticancer targets. Nat. Commun.","DOI":"10.2210\/pdb6co4\/pdb"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"11917","DOI":"10.1021\/acsomega.8b01479","article-title":"Covalent Rpn13-Binding Inhibitors for the Treatment of Ovarian Cancer","volume":"3","author":"Anchoori","year":"2018","journal-title":"ACS Omega"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"6312","DOI":"10.1021\/jacs.5b02069","article-title":"A reversible and highly selective inhibitor of the proteasomal ubiquitin receptor rpn13 is toxic to multiple myeloma cells","volume":"137","author":"Trader","year":"2015","journal-title":"J. Am. Chem. Soc."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/513481a","article-title":"Chemistry: Chemical con artists foil drug discovery","volume":"513","author":"Baell","year":"2014","journal-title":"Nature"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1038\/s41375-019-0467-z","article-title":"Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma","volume":"33","author":"Song","year":"2019","journal-title":"Leukemia"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cbpa.2019.02.022","article-title":"Targeted protein degradation: Elements of PROTAC design","volume":"50","author":"Paiva","year":"2019","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ddtec.2019.01.002","article-title":"PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future","volume":"31","author":"Pettersson","year":"2019","journal-title":"Drug Discov. Today Technol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41573-019-0047-y","article-title":"Targeted protein degradation: Expanding the toolbox","volume":"18","author":"Schapira","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"12936","DOI":"10.1021\/ja075469+","article-title":"Periodate-triggered cross-linking reveals Sug2\/Rpt4 as the molecular target of a peptoid inhibitor of the 19S proteasome regulatory particle","volume":"129","author":"Lim","year":"2007","journal-title":"J. Am. Chem. Soc."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"7750","DOI":"10.1021\/ja072027p","article-title":"Identification of a peptoid inhibitor of the proteasome 19S regulatory particle","volume":"129","author":"Lim","year":"2007","journal-title":"J. Am. Chem. Soc."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1073\/pnas.1619067114","article-title":"Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers","volume":"114","author":"Tsvetkov","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Acosta-Alvear, D., Cho, M.Y., Wild, T., Buchholz, T.J., Lerner, A.G., Simakova, O., Hahn, J., Korde, N., Landgren, O., and Maric, I. (2015). Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits. eLife.","DOI":"10.7554\/eLife.08153.019"},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Tsvetkov, P., Mendillo, M.L., Zhao, J., Carette, J.E., Merrill, P.H., Cikes, D., Varadarajan, M., van Diemen, F.R., Penninger, J.M., and Goldberg, A.L. (2015). Compromising the 19S proteasome complex protects cells from reduced flux through the proteasome. eLife.","DOI":"10.7554\/eLife.08467.021"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bjh.15210","article-title":"Resistance to proteasome inhibitors and other targeted therapies in myeloma","volume":"182","author":"Kuss","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_173","first-page":"249","article-title":"Understanding resistance to combination chemotherapy","volume":"15","author":"Pritchard","year":"2012","journal-title":"Drug Resist. Updat. Rev. Comment. Antimicrob. Anticancer Chemother."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1158\/2159-8290.CD-17-1226","article-title":"Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer","volume":"8","author":"Corcoran","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/2159-8290.CD-11-0341","article-title":"EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib","volume":"2","author":"Corcoran","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature10868","article-title":"Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR","volume":"483","author":"Prahallad","year":"2012","journal-title":"Nature"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.molcel.2010.09.012","article-title":"Proteasomal degradation is transcriptionally controlled by TCF11 via an ERAD-dependent feedback loop","volume":"40","author":"Steffen","year":"2010","journal-title":"Mol. Cell"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.molcel.2010.02.029","article-title":"Transcription factor Nrf1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cells","volume":"38","author":"Radhakrishnan","year":"2010","journal-title":"Mol. Cell"},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"Radhakrishnan, S.K., den Besten, W., and Deshaies, R.J. (2014). p97-dependent retrotranslocation and proteolytic processing govern formation of active Nrf1 upon proteasome inhibition. eLife.","DOI":"10.1101\/001602"},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"Koizumi, S., Irie, T., Hirayama, S., Sakurai, Y., Yashiroda, H., Naguro, I., Ichijo, H., Hamazaki, J., and Murata, S. (2016). The aspartyl protease DDI2 activates Nrf1 to compensate for proteasome dysfunction. eLife.","DOI":"10.7554\/eLife.18357.011"},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Lehrbach, N.J., and Ruvkun, G. (2016). Proteasome dysfunction triggers activation of SKN-1A\/Nrf1 by the aspartic protease DDI-1. eLife, 5.","DOI":"10.7554\/eLife.17721"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1021\/acscentsci.7b00224","article-title":"Inhibition of NGLY1 Inactivates the Transcription Factor Nrf1 and Potentiates Proteasome Inhibitor Cytotoxicity","volume":"3","author":"Tomlin","year":"2017","journal-title":"ACS Cent. Sci."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.cell.2019.03.035","article-title":"Protein Sequence Editing of SKN-1A\/Nrf1 by Peptide:N-Glycanase Controls Proteasome Gene Expression","volume":"177","author":"Lehrbach","year":"2019","journal-title":"Cell"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gene.2015.11.021","article-title":"The cytoplasmic peptide:N-glycanase (NGLY1) - Structure, expression and cellular functions","volume":"577","author":"Suzuki","year":"2016","journal-title":"Gene"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/s41589-019-0291-9","article-title":"Mitochondrial metabolism promotes adaptation to proteotoxic stress","volume":"15","author":"Tsvetkov","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.gene.2016.02.042","article-title":"Structure and function of the AAA+ ATPase p97\/Cdc48p","volume":"583","author":"Xia","year":"2016","journal-title":"Gene"},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Ye, Y., Tang, W.K., Zhang, T., and Xia, D. (2017). A Mighty \u201cProtein Extractor\u201d of the Cell: Structure and Function of the p97\/CDC48 ATPase. Front. Mol. Biosci.","DOI":"10.3389\/fmolb.2017.00039"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.molcel.2017.10.028","article-title":"VCP\/p97-Mediated Unfolding as a Principle in Protein Homeostasis and Signaling","volume":"69","author":"Meyer","year":"2018","journal-title":"Mol. Cell"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/414652a","article-title":"The AAA ATPase Cdc48\/p97 and its partners transport proteins from the ER into the cytosol","volume":"414","author":"Ye","year":"2001","journal-title":"Nature"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/ncb2407","article-title":"Emerging functions of the VCP\/p97 AAA-ATPase in the ubiquitin system","volume":"14","author":"Meyer","year":"2012","journal-title":"Nat. Cell Biol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41594-018-0085-x","article-title":"Structure of the Cdc48 ATPase with its ubiquitin-binding cofactor Ufd1-Npl4","volume":"25","author":"Bodnar","year":"2018","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"Bodnar, N., and Rapoport, T. (2017). Toward an understanding of the Cdc48\/p97 ATPase. F1000Research.","DOI":"10.12688\/f1000research.11683.1"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1126\/science.aad7974","article-title":"2.3 \u00c5 resolution cryo-EM structure of human p97 and mechanism of allosteric inhibition","volume":"351","author":"Banerjee","year":"2016","journal-title":"Science"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"49609","DOI":"10.1074\/jbc.M408695200","article-title":"The AAA ATPase p97\/VCP interacts with its alternative co-factors, Ufd1-Npl4 and p47, through a common bipartite binding mechanism","volume":"279","author":"Bruderer","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1158\/1535-7163.MCT-17-0233","article-title":"The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma","volume":"16","author":"Aftab","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/ng1332","article-title":"Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein","volume":"36","author":"Watts","year":"2004","journal-title":"Nat. Genet."},{"key":"ref_197","doi-asserted-by":"crossref","unstructured":"Tang, W.K., and Xia, D. (2016). Mutations in the Human AAA+ Chaperone p97 and Related Diseases. Front. Mol. Biosci.","DOI":"10.3389\/fmolb.2016.00079"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1073\/pnas.1706205114","article-title":"Ubiquitin- and ATP-dependent unfoldase activity of P97\/VCP\u2022NPLOC4\u2022UFD1L is enhanced by a mutation that causes multisystem proteinopathy","volume":"114","author":"Blythe","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1016\/j.str.2019.09.011","article-title":"Multisystem Proteinopathy Mutations in VCP\/p97 Increase NPLOC4\u00b7UFD1L Binding and Substrate Processing","volume":"27","author":"Blythe","year":"2019","journal-title":"Structure"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"9472","DOI":"10.1158\/0008-5472.CAN-07-0568","article-title":"Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics","volume":"67","author":"Yang","year":"2007","journal-title":"Cancer Res."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nm.4474","article-title":"A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment","volume":"24","author":"Hyer","year":"2018","journal-title":"Nat. Med."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"7988","DOI":"10.18632\/oncotarget.2431","article-title":"Screening for E3-ubiquitin ligase inhibitors: Challenges and opportunities","volume":"5","author":"Rotblat","year":"2014","journal-title":"Oncotarget"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.cub.2007.01.027","article-title":"Ubiquitination of RIP1 regulates an NF-kappaB-independent cell-death switch in TNF signaling","volume":"17","author":"Skountzos","year":"2007","journal-title":"Curr. Biol. CB"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"6252","DOI":"10.1038\/onc.2008.302","article-title":"IAP-targeted therapies for cancer","volume":"27","author":"LaCasse","year":"2008","journal-title":"Oncogene"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2008.03.036","article-title":"TNF-alpha induces two distinct caspase-8 activation pathways","volume":"133","author":"Wang","year":"2008","journal-title":"Cell"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/nature07884","article-title":"An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer","volume":"458","author":"Soucy","year":"2009","journal-title":"Nature"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1182\/blood-2017-09-805895","article-title":"Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML","volume":"131","author":"Swords","year":"2018","journal-title":"Blood"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1078-0432.CCR-15-1338","article-title":"Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924\/MLN4924) in Patients with Advanced Solid Tumors","volume":"22","author":"Sarantopoulos","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/nature24006","article-title":"USP7 small-molecule inhibitors interfere with ubiquitin binding","volume":"550","author":"Kategaya","year":"2017","journal-title":"Nature"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature24451","article-title":"Molecular basis of USP7 inhibition by selective small-molecule inhibitors","volume":"550","author":"Turnbull","year":"2017","journal-title":"Nature"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.chembiol.2017.09.003","article-title":"Structure-Guided Development of a Potent and Selective Non-covalent Active-Site Inhibitor of USP7","volume":"24","author":"Lamberto","year":"2017","journal-title":"Cell Chem. Biol."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nchembio.2528","article-title":"Discovery and characterization of highly potent and selective allosteric USP7 inhibitors","volume":"14","author":"Gavory","year":"2018","journal-title":"Nat. Chem. Biol."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s11684-016-0488-1","article-title":"Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors","volume":"10","author":"Wang","year":"2016","journal-title":"Front. Med."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2174\/1568026616666160719163839","article-title":"Targeting Non-Catalytic Cysteine Residues Through Structure-Guided Drug Discovery","volume":"17","author":"Hallenbeck","year":"2017","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11899-019-00512-0","article-title":"Targeting BTK in CLL: Beyond Ibrutinib","volume":"14","author":"Bond","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_217","doi-asserted-by":"crossref","unstructured":"Wu, J., Zhang, M., and Liu, D. (2016). Acalabrutinib (ACP-196): A selective second-generation BTK inhibitor. J. Hematol. Oncol.","DOI":"10.1186\/s13045-016-0250-9"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"key":"ref_219","doi-asserted-by":"crossref","unstructured":"Lee, M.J., Lee, B.-H., Hanna, J., King, R.W., and Finley, D. (2011). Trimming of ubiquitin chains by proteasome-associated deubiquitinating enzymes. Mol. Cell Proteom. MCP.","DOI":"10.1074\/mcp.R110.003871"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nature09299","article-title":"Enhancement of proteasome activity by a small-molecule inhibitor of USP14","volume":"467","author":"Lee","year":"2010","journal-title":"Nature"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/s41422-018-0091-x","article-title":"Small molecule inhibitors reveal allosteric regulation of USP14 via steric blockade","volume":"28","author":"Wang","year":"2018","journal-title":"Cell Res."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/nm.2536","article-title":"Inhibition of proteasome deubiquitinating activity as a new cancer therapy","volume":"17","author":"Brnjic","year":"2011","journal-title":"Nat. Med."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/MOT.0b013e328348c0e5","article-title":"Proteasome inhibitor treatment of antibody-mediated allograft rejection","volume":"16","author":"Woodle","year":"2011","journal-title":"Curr. Opin. Organ. Transpl."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1111\/ajt.14222","article-title":"Proteasome Inhibitor Carfilzomib-Based Therapy for Antibody-Mediated Rejection of the Pulmonary Allograft: Use and Short-Term Findings","volume":"17","author":"Ensor","year":"2017","journal-title":"Am. J. Transpl. Off. J. Am. Soc. Transpl. Am. Soc. Transpl. Surg."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1172\/JCI90597","article-title":"Antibody-mediated rejection across solid organ transplants: Manifestations, mechanisms, and therapies","volume":"127","author":"Valenzuela","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1097\/TP.0b013e3181a4b91b","article-title":"Abrogation of anti-HLA antibodies via proteasome inhibition","volume":"87","author":"Trivedi","year":"2009","journal-title":"Transplantation"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1089\/ars.2014.5892","article-title":"Review of bortezomib treatment of antibody-mediated rejection in renal transplantation","volume":"21","author":"Ejaz","year":"2014","journal-title":"Antioxid. Redox Signal."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"252","DOI":"10.5414\/CN109278","article-title":"Durable renal response after combination of bortezomib, corticosteroids, rituximab, and plasmapheresis for late antibody-mediated renal transplant rejection","volume":"89","author":"Ding","year":"2018","journal-title":"Clin. Nephrol."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/TP.0b013e31823f7eea","article-title":"Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients","volume":"93","author":"Morrow","year":"2012","journal-title":"Transplantation"},{"key":"ref_230","first-page":"443","article-title":"Bortezomib-based treatment of antibody mediated rejection in pancreas allograft recipients","volume":"45","author":"Govil","year":"2009","journal-title":"Clin. Transpl."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.healun.2013.08.017","article-title":"Bortezomib rescue therapy in a patient with recurrent antibody-mediated rejection after lung transplantation","volume":"32","author":"Baum","year":"2013","journal-title":"J. Heart Lung Transpl. Off. Publ. Int. Soc. Heart Transpl."},{"key":"ref_232","first-page":"40","article-title":"The proteasome as a target to combat malaria: Hits and misses","volume":"198","author":"Krishnan","year":"2018","journal-title":"Transl. Res. J. Lab. Clin. Med."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nature16936","article-title":"Structure- and function-based design of Plasmodium-selective proteasome inhibitors","volume":"530","author":"Li","year":"2016","journal-title":"Nature"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"6370","DOI":"10.1002\/anie.201602519","article-title":"Rational Design of Proteasome Inhibitors as Antimalarial Drugs","volume":"55","author":"Groll","year":"2016","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1021\/cb5001263","article-title":"Assessing subunit dependency of the Plasmodium proteasome using small molecule inhibitors and active site probes","volume":"9","author":"Li","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpddr.2011.12.001","article-title":"The proteasome of malaria parasites: A multi-stage drug target for chemotherapeutic intervention?","volume":"2","author":"Aminake","year":"2012","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1128\/AAC.00088-09","article-title":"The proteasome inhibitor epoxomicin has potent Plasmodium falciparum gametocytocidal activity","volume":"53","author":"Czesny","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.chembiol.2012.09.019","article-title":"Validation of the proteasome as a therapeutic target in Plasmodium using an epoxyketone inhibitor with parasite-specific toxicity","volume":"19","author":"Li","year":"2012","journal-title":"Chem. Biol."},{"key":"ref_239","doi-asserted-by":"crossref","unstructured":"Becker, S.H., and Darwin, K.H. (2017). Bacterial Proteasomes: Mechanistic and Functional Insights. Microbiol. Mol. Biol. Rev. MMBR.","DOI":"10.1128\/MMBR.00036-16"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1111\/j.1365-2958.2005.05035.x","article-title":"Mycobacterium tuberculosis prcBA genes encode a gated proteasome with broad oligopeptide specificity","volume":"59","author":"Lin","year":"2006","journal-title":"Mol. Microbiol."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/j.1365-2958.2005.05036.x","article-title":"Structure of the Mycobacterium tuberculosis proteasome and mechanism of inhibition by a peptidyl boronate","volume":"59","author":"Hu","year":"2006","journal-title":"Mol. Microbiol."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2958.2004.04403.x","article-title":"Characterization of a Mycobacterium tuberculosis proteasomal ATPase homologue","volume":"55","author":"Darwin","year":"2005","journal-title":"Mol. Microbiol."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1126\/science.1091176","article-title":"The proteasome of Mycobacterium tuberculosis is required for resistance to nitric oxide","volume":"302","author":"Darwin","year":"2003","journal-title":"Science"},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S1473-3099(19)30420-7","article-title":"Improving the cascade of global tuberculosis care: Moving from the \u201cwhat\u201d to the \u201chow\u201d of quality improvement","volume":"19","author":"Agins","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"9246","DOI":"10.1021\/acs.jmedchem.9b01187","article-title":"Selective Phenylimidazole-Based Inhibitors of the Mycobacterium tuberculosis Proteasome","volume":"62","author":"Zhan","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1021\/acsinfecdis.6b00172","article-title":"Rational Design of Selective and Bioactive Inhibitors of the Mycobacterium tuberculosis Proteasome","volume":"3","author":"Totaro","year":"2017","journal-title":"ACS Infect. Dis."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/3\/671\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T08:54:45Z","timestamp":1760172885000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/3\/671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,5]]},"references-count":246,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,2]]}},"alternative-id":["molecules25030671"],"URL":"https:\/\/doi.org\/10.3390\/molecules25030671","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,5]]}}}